The development of novel and selective p56lck tyrosine kinase inhibitors.
作者信息
Bullington J L, Cameron J C, Davis J E, Dodd J H, Harris C A, Henry J R, Pellegrino-Gensey J L, Rupert K C, Siekierka J J
机构信息
R. W. Johnson Pharmaceutical Research Institute, Raritan, NJ 08869, USA.
出版信息
Bioorg Med Chem Lett. 1998 Sep 22;8(18):2489-94. doi: 10.1016/s0960-894x(98)00445-4.
PMID:9873567
Abstract
Early T-cell receptor mediated signal transduction involves the activation of several tyrosine protein kinases. One of these tyrosine kinases, p56lck, is expressed primarily in T-cells and Natural Killer (NK) cells and has been shown to be critical for their proliferative and effector functions. Indandiones have been identified as a potent and selective chemical class that inhibits p56lck.
摘要
Zotero 插件